

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>JAFCO Super V3 Investment Limited Partnership</u> (Last) (First) (Middle) OTEMACHI FIRST SQUARE, WEST TOWER 11F, 1-5-1, OTENACHI CHIYODA-KU (Street) TOKYO, JAPAN M0 100-0004 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Eleven Biotherapeutics, Inc. [EBIO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/11/2014	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/11/2014		P		219,790	A	\$10	219,790	D	
Common Stock	02/11/2014		C		1,574,803	A	(1)	1,794,593	D	
Common Stock	02/11/2014		C		232,105	A	(1)	2,026,698	D	
Common Stock	02/11/2014		M		60,853	A	(2)	2,087,551	D	
Common Stock	02/11/2014		M		39,740	A	(2)	2,127,291	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	02/11/2014		C		1,574,803		(1)	(1)	Common Stock	1,574,803	\$0.00	0	D	
Series B Preferred Stock	(1)	02/11/2014		C		232,105		(1)	(1)	Common Stock	232,105	\$0.00	0	D	
Common Stock Warrant (right to purchase)	(2)	02/11/2014		M		61,242		(2)	(2)	Common Stock	60,853	\$0.00	0	D	
Common Stock Warrant (right to purchase)	(2)	02/11/2014		M		39,994		(2)	(2)	Common Stock	39,740	\$0.00	0	D	

Explanation of Responses:

- The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Person converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on a 1-for-1 basis.
- The Reporting Person exercised warrants to purchase shares of Common Stock by cashless exercise immediately prior to the closing of the Issuer's initial public offering.

/s/ Hironori Hozoji 02/12/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.